Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    amaze

Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04868500
Recruitment Status : Recruiting
First Posted : May 3, 2021
Last Update Posted : May 17, 2021
Sponsor:
Collaborators:
Massachusetts General Hospital
Evidera, Inc.
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.

Condition or disease Intervention/treatment Phase
Asthma Device: AMAZE™ Disease Management Platform Not Applicable

Detailed Description:
AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of patients throughout their patient care journey. AMAZE™ integrates multiple systems, including a patient mobile application where patients can enter daily symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials. Implementation of AMAZE™ within clinical practice has not yet been evaluated. The results from this study will be used to inform any changes or modifications that need to be made to the technology platform, its implementation process, and explore impact on clinical outcomes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform, A Clinical Pilot Study
Actual Study Start Date : April 27, 2021
Estimated Primary Completion Date : November 16, 2021
Estimated Study Completion Date : December 16, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: Clinical Pilot
Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and MGH clinical staff.
Device: AMAZE™ Disease Management Platform
The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.




Primary Outcome Measures :
  1. Patient app usage [ Time Frame: Up to 6 months ]
    Patient app usage will be measured as the number of days the patient engages (i.e., completes daily log, sends a message) with the app at least once a day during the study period.

  2. Clinician Dashboard Usage [ Time Frame: Up to 6 months ]
    Clinician dashboard usage will be measured as the mean number of days per week/month that the clinical site staff accessed the AMAZE™ dashboard over the 6-month period.

  3. Daily Asthma status [ Time Frame: Up to 6 months ]
    Patient daily asthma status (bad, okay, good) reported on the app will be described weekly during Month 1, and then per month from Month 1 through Month 6 pending availability of data after Month 1.

  4. Symptoms and Triggers [ Time Frame: Up to 6 months ]
    Frequency of symptoms and frequency of triggers (for those that reported symptoms) reported on the app will be described weekly during Months 1, and then per month from Month 1 through Month 6 pending availability of data after Month 1.

  5. Self-Reported Rescue Medication Usage [ Time Frame: Up to 6 months ]
    The number of times per month a patient used rescue medication as well as visited the emergency room or urgent care as reported on the app will be described from Month 1 through Month 6.


Secondary Outcome Measures :
  1. Impact of AMAZE™ on patient visits [ Time Frame: Up to 6 months ]
    The impact of AMAZE™ on patient visits will be measured as the frequency of patients who select "agree" or "strongly agree" in response to the 9-items in the patient visit experience survey.

  2. ER visits and Hospitalization avoidance [ Time Frame: Up to 6 months ]
    The impact of AMAZE™ on ER and hospitalizations will be measured as the frequency of patients who report "agree" or "strongly agree" with the item "The visit helped avoid an ER or Urgent Care center visit or hospitalization" from the patient visit experience survey.

  3. Patient Perception of Appointment Discussions and Taking Part in Asthma Decisions [ Time Frame: Up to 6 Months ]
    The impact of AMAZE™ on improved patient communication with their provider will be measured as the frequency of patients who report "agree" or "strongly agree" with the items "the app helped me discuss my asthma with my healthcare provider(s) during my most recent visit" and "I was included in making decisions about my asthma treatment during my most recent visit" on the patient visit experience survey.

  4. Patient Perception of Usability and Design of Mobile app [ Time Frame: Up to 6 month ]
    The usability of the AMAZE™ app will be measured by the frequency of patients who rate the app excellent (SUS score >80.3), good (68-80.3), okay (68), poor (51-68), or awful (<51) at months 1 and 6

  5. Clinical Staff Perception of Usability and Design of Dashboard [ Time Frame: Up to 6 months ]
    The usability of the AMAZE™ dashboard will be measured by the frequency of clinical staff who rate the app excellent (SUS score >80.3), good (68-80.3), okay (68), poor (51-68), or awful (<51) at months 1 and 6

  6. Evaluate ease of implementation of AMAZE™ in clinical setting [ Time Frame: Up to 6 months ]
    The ease of implementation of AMAZE™ will be measured by the frequency of clinical staff who report "very easy" or "somewhat easy" to the question "How would you rate the overall ease of implementing AMAZE™ on a platform into your clinical practice?" in the post-study survey at month 6.

  7. Evaluate impact of AMAZE™ on managing patients [ Time Frame: Up to 6 months ]
    The impact of AMAZE™ on managing patients will be measured by the frequency of clinical staff who report "moderately" or "very well" to the question "Did the AMAZE™ help you manage your patients?" in the post-study survey at month 6.

  8. Evaluate Perceived Benefit of AMAZE™ in clinical setting [ Time Frame: Up to 6 months ]
    The perceived benefit of AMAZE™ will be evaluated by the frequency of clinical staff who endorse different perceived benefits based on the item "what did you find the most useful about the AMAZE™ platform?" in the post-study survey at month 6.

  9. Evaluate Perceived Disadvantages of AMAZE™ in clinical setting [ Time Frame: Up to 6 months ]
    The perceived disadvantages of AMAZE™ will be evaluated by the frequency of clinical staff who endorse different perceived disadvantages based on the item "what did you find the least useful or cumbersome about the AMAZE™ platform?" in the post-study survey at month 6.

  10. Evaluate patient satisfaction with healthcare experience [ Time Frame: Up to 6 months ]
    Patient satisfaction with their healthcare experience will be evaluated using the PSQ-18 items and subscale scores (General Satisfaction, Technical Quality, Interpersonal Manner, Communication, Financial Aspects, Time Spent with Doctor, Accessibility and Convenience) at Month 6.

  11. Evaluate patient satisfaction with app [ Time Frame: Up to 6 months ]
    Satisfaction with the app features will be measured by the frequency of patients who report satisfaction on a scale of 1 (lowest satisfaction) to 5 (highest satisfaction) at months 1, 3, and 6.


Other Outcome Measures:
  1. Evaluating change in medication [ Time Frame: Up to 6 months ]
    Medication changes from baseline to six-month will be evaluated.

  2. Evaluating clinician-reported asthma control [ Time Frame: Up to 6 months ]
    Asthma control was assessed by a clinician completed single item; asthma control at baseline will be evaluated.

  3. Evaluating patient-reported asthma control [ Time Frame: Up to 6 months ]
    The impact of AMAZE™ on asthma control will be measured as the frequency of patients considered to be poorly controlled (ACT scores ≤15), not well-controlled (ACT scores 16-19, and well-controlled (ACT scores ≥20) from Month 1 through Month 6 .

  4. Changes in asthma symptoms before clinical visit [ Time Frame: Up to 6 months ]
    Frequency of symptoms reported in the patient daily log up to a week proceeding a clinical visit during the study period will be evaluated to assess trends in symptoms that may have triggered a visit.

  5. Changes in medication after clinical visit [ Time Frame: Up to 6 months ]
    Following a clinical visit any time during the study period, medication changes will be monitored to determine if any changes were prompted by the visit.

  6. Characteristics of Patients Most Likely to Benefit from AMAZE™ [ Time Frame: Up to 6 months ]
    Demographic information reported by the patient and clinical information reported by the clinical staff will be used and stratified by subgroups, including age, asthma severity, education, and ethnicity, to evaluate characteristics of patients most likely to benefit from AMAZE™



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • >18 years of age at the time of enrollment
  • Clinically confirmed diagnosis of asthma
  • Access to a smartphone with internet access with the following requirements: iOS (Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating System 8.0 or newer)
  • Able to understand and speak English sufficiently to be able to use the AMAZE™ patient app
  • Willingness to participate in a telephone interview and be audio-recorded
  • Consenting to participate in the study

Exclusion Criteria:

  • Current diagnosis of active chronic obstructive pulmonary disease (COPD) or any pulmonary diagnosis other than asthma
  • Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, or insufficient knowledge of the English language that, in the opinion of the investigator, would interfere with his or her ability to agree to participate and/or complete the ACT™.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04868500


Contacts
Layout table for location contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com

Locations
Layout table for location information
United States, Massachusetts
Research Site Recruiting
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
AstraZeneca
Massachusetts General Hospital
Evidera, Inc.
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT04868500    
Other Study ID Numbers: N4280000000
First Posted: May 3, 2021    Key Record Dates
Last Update Posted: May 17, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases